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Letter to the Editor
Table 1
Allelic Tests of SNPs Associated with Late-Onset PD
dbSNP
ACCESSION
NUMBERa GENE CHROMOSOME
POSITION
(Mbp)
CASEb CONTROLb ALLELIC TEST
11 12 22 Sum MAFc 11 12 22 Sum MAF OR (95% CI) Pd
Power
(%)
rs7702187 SEMA5A 5 9.4 9 86 215 310 .168 8 83 217 308 .161 1.05 (.78–1.42) .74 97
rs10200894 2 228.6 1 48 262 311 .080 3 66 238 307 .117 .66 (.45–.96) .03 93
rs2313982 4 139.1 2 47 258 307 .083 4 45 256 305 .087 .95 (.64–1.42) .81 96
rs17329669 7 36.6 10 73 224 307 .151 3 60 246 309 .107 1.49 (1.07–2.09) .02 94
rs7723605 5 5.4 6 86 218 310 .158 5 70 232 307 .130 1.25 (.91–1.72) .17 95
ss46548856 10 59.0 2 52 256 310 .090 4 61 241 306 .113 .78 (.54–1.13) .19 92
rs16851009 2 166.5 6 53 251 310 .105 4 45 259 308 .086 1.24 (.85–1.82) .26 94
rs2245218 PRDM2 1 13.9 12 64 234 310 .142 6 83 215 304 .156 .89 (.65–1.22) .48 94
rs7878232:
Male and female X 150.5 … … … 307 .230 … … … 301 .244 .92 (.71–1.20) .55 66
Female … … 13 47 101 161 .227 9 61 89 159 .248 .89 (.62–1.28) .52 …
Male … … … … … 146 .233 … … … 142 .239 .96 (.56–1.66) .90 …
rs1509269 4 139.1 5 63 243 311 .117 7 65 235 307 .129 .90 (.64–1.26) .55 92
rs11737074 4 125.4 16 116 178 310 .239 13 102 192 307 .208 1.19 (.91–1.56) .20 90
rs7520966 LOC200008 1 54.4 16 117 175 308 .242 19 129 160 308 .271 .86 (.66–1.11) .24 97
a The top 11 markers are presented in the same order as in table 4 in Maraganore et al.1
b Counts of genotype 11, 12, and 22.
c Minor-allele frequency.
d Two-sided P value for all strata and for female and male substrata in rs7878232.
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To the Editor:
To validate associations of SNPs that Maraganore et al.1
reported as associated with Parkinson disease (PD [MIM
168600]), we constructed a case-control series from PD
cases and matched population/convenience controls that
are available through the National Institute of Neuro-
logical Disorders and Stroke (NINDS) Human Genetics
Resources at the Coriell Institute. Cases met United
Kingdom Brain Bank criteria for idiopathic PD,2 and
controls were neurologically normal. This series com-
prises 311 pairs of age- and sex-matched cases and con-
trols. Cases had an age at disease onset ranging from
50 to 87 years (average [SD] 63.8  8.9 years) and
were sampled at the age of 52–92 years (average [SD]
70.1  8.5 years). Controls were also sampled at the
age of 52–92 years (average [SD] 70.2  8.5 years).
All cases and controls are white, and each group includes
165 females (53.1%) and 146 males (46.9%), respec-
tively. Cases in this series do not carry the Gly2019Ser
mutation in LRRK2 [MIM 609007], which may occur
in idiopathic PD,3 and several tests did not reveal evi-
dence of significant population stratification for 78 in-
dividually genotyped null markers (data not shown). We
individually genotyped the 11 SNPs that were reported
significant and one of the two SNPs that map to the
PARK10 [MIM 606852] locus (the two reported-sig-
nificant SNPs are highly correlated: ), using2r p 0.99
allele-specific real-time PCR in our PD case-control sam-
ple set. Cases and controls were run on the same plate
in a blinded fashion. Our genotyping method has an
overall accuracy of 199%.4 As an additional indication
of genotyping quality, we calculated deviation from
Hardy-Weinberg equilibrium (HWE) in cases and con-
trols. One marker had an HWE exact P value of !.05
(.017 for rs2245218 in cases), but further examination
of our genotype data did not reveal questionable calls.
Therefore, these data were included in our analysis. All
SNPs were tested for allelic association with PD with
the use of x2 statistics to calculate two-sided P values
(table 1). Power calculations were done for a sample size
of 311 pairs for each SNP, with the use of a one-sided
allelic x2-hypothesis test at a significance level of 0.05
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and with the assumption that the control-allele frequen-
cies of the unrelated controls and odds ratios (ORs) in
table 4 in Maraganore et al.1 are true population pa-
rameters. Power calculation for rs7520966 was based
on the tier 2 OR given in the text of Maraganore et al.,1
since it did not appear in their table 4.
Two markers, rs10200894 and rs17329669, were rep-
licated in our sample set at ( andP ! .1 Pp .03 Pp
, respectively) with the same risk alleles as in Mar-.02
aganore et al.,1 although with slightly lower ORs.
rs10200894 is an intergenic variant located on chro-
mosome 2 near a linkage peak previously identified in
late-onset PD,5 and rs17329669 is in an intergenic re-
gion on chromosome 7. Further investigations in these
regions, including further genetic mapping and the iden-
tification of potential causative variants, are thus war-
ranted. Indeed, several SNPs in the vicinity of rs10200894
and rs17329669 reached significance in the Maraganore
et al.1 discovery sample set ( ) but were not fol-P ! .05
lowed up because they did not reach their significance
threshold of . ELMO1 [MIM 606420], a geneP ! .01
whose product is predicted to be involved in apoptosis
and cell migration, resides in a region that, according
to the HapMap, is in high linkage disequilibrium with
rs17329669. The more abundant splice variant of
ELMO1 appears to be exclusively expressed in brain6
and, thus, constitutes an excellent biological candidate
gene for PD. All other markers were not significant in our
sample set at the 0.1 level, including the marker reported
most significant in SEMA5A [MIM 609297] and the
marker in LOC200008, which maps to the PARK10 locus
that appears to affect both disease risk and age of onset.7–
9 Our failure to replicate the majority of the associated
markers may be due to false-positive results in the initial
study or to locus heterogeneity. Although the power in
our validation sample set is90% for 11 of the 12 tested
SNPs, this may be an overestimation due to an OR in-
flation (“jackpot effect”) in the original study. In addition,
our sample set included only late-onset cases, commonly
defined by age at onset 150 years, whereas the study by
Maraganore et al. included both early- and late-onset
cases.1 Thus, it is possible that nonreplicated markers are
associated with early-onset PD but make a lesser contri-
bution to the more common, late-onset form of the dis-
ease. Additional studies are required to further assess the
association of these markers with PD.
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